Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 741 to 750 of 1144 total matches.

Nefazodone for Depression

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 1995  (Issue 946)
may be 50 to 200 mg b.i.d. CONCLUSION — Available data are inadequate to determine how nefazodone compares ...
Nefazodone (Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone (Desyrel, and others).
Med Lett Drugs Ther. 1995 Apr 14;37(946):33-5 |  Show IntroductionHide Introduction

Varicella Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 1995  (Issue 951)
simultaneously with measles-mumps-rubella (MMR) vaccine, using separate syringes and injection sites. No data ...
A live attenuated varicella vaccine (Varivax - Merck) has been approved for marketing by the US Food and Drug Administration. The Oka/Merck strain used in the vaccine is attenuated by passage in human and embryonic guinea pig cell cultures.
Med Lett Drugs Ther. 1995 Jun 23;37(951):55-7 |  Show IntroductionHide Introduction

Echinacea for Prevention and Treatment of Upper Respiratory Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2002  (Issue 1127)
they felt better. One study did not use standardized dosage or record data, but relied on the subjects ...
Echinacea, a plant also called purple coneflower, is widely used as a dietary supplement for prevention and treatment of colds.
Med Lett Drugs Ther. 2002 Apr 1;44(1127):29-30 |  Show IntroductionHide Introduction

Fulvestrant (Faslodex) for Advanced Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2002  (Issue 1135)
with combined data and updated results found a longer duration of response with fulvestrant, 16.7 vs. 13.6 ...
Fulvestrant (Faslodex -- AstraZeneca), an estrogen receptor antagonist given intramuscularly (IM) once a month, was recently approved by the FDA for treatment of hormone-receptor-positive metastatic breast cancer in postmenopausal women with disease progession on tamoxifen (Nolvadex, and others) or another antiestrogen.
Med Lett Drugs Ther. 2002 Jul 22;44(1135):65-6 |  Show IntroductionHide Introduction

Alefacept (Amevive) For Treatment of Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 2003  (Issue 1154)
for more than a year, but the data are still incomplete (GG Krueger et al, J Am Acad Dermatol 2002; 47:821 ...
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.
Med Lett Drugs Ther. 2003 Apr 14;45(1154):31-2 |  Show IntroductionHide Introduction

Menostar - A Low-Dose Estrogen Patch for Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Aug 30, 2004  (Issue 1190)
and decreased by 0.8% with placebo (B Ettinger et al, Obstet Gynecol 2004; 104:443). No data are available ...
The FDA has approved a new low-dose estrogen patch (Menostar - Berlex) for prevention of osteoporosis in postmenopausal women. Unlike other estrogen patches, it is not approved for treatment of hot flashes or other menopausal symptoms. Promotional material from the manufacturer suggests that this low dose of estrogen could prevent osteoporosis without some of the adverse effects of higher doses.
Med Lett Drugs Ther. 2004 Aug 30;46(1190):69-70 |  Show IntroductionHide Introduction

Entecavir (Baraclude) for Chronic Hepatitis B

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 2005  (Issue 1210)
to most recent data (April 30, 2005) available from NDC Health, a healthcare information services ...
Entecavir (Baraclude - Bristol-Myers Squibb), a nucleoside analog, has been approved by the FDA for treatment of adults with active chronic hepatitis B virus (HBV) infection.
Med Lett Drugs Ther. 2005 Jun 6;47(1210):47-8 |  Show IntroductionHide Introduction

Vagus Nerve Stimulation for Depression

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2005  (Issue 1211)
the electric leads of the device; special precautions may be needed. Preliminary data suggest ...
A device that stimulates the vagus nerve was approved by the FDA in July 1997 for treatment of refractory epilepsy and is now considered "approvable" for treatment-resistant depression.
Med Lett Drugs Ther. 2005 Jun 20;47(1211):50 |  Show IntroductionHide Introduction

Second-Generation Antipsychotics - Aripiprazole Revisited

   
The Medical Letter on Drugs and Therapeutics • Oct 10, 2005  (Issue 1219)
, based on most recent data (August 31, 2005) available from NDCHealth, a healthcare information services ...
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a second-generation (atypical) antipsychotic drug, was approved by the FDA in 2002 for treatment of schizophrenia and more recently for bipolar disorder as well. It has been promoted as causing fewer adverse effects than other antipsychotics, without sacrificing efficacy.
Med Lett Drugs Ther. 2005 Oct 10;47(1219):81-2 |  Show IntroductionHide Introduction

Chromium Supplementation

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006  (Issue 1226)
and effect have not been established. 12 Data on long-term safety are lacking. CONCLUSION — The best ...
Chromium is marketed as a dietary supplement, usually containing 20-500 mcg of a chromium salt. It has been promoted for weight loss, muscle building, and for prevention and treatment of diabetes, among other claims. As a dietary supplement, chromium can be sold without proof of efficacy or safety.
Med Lett Drugs Ther. 2006 Jan 16;48(1226):7-8 |  Show IntroductionHide Introduction